

Appendix 7: Forest plots [posted as supplied by author]

Figure 3: Zanamivir versus placebo for treatment. Time to first alleviation of symptoms in adult treatment [days].




Figure 4: Zanamivir versus placebo for treatment. Time to first alleviation of symptoms in children (days).




Figure 5: Time to first alleviation of symptoms in adults by infection status




Figure 6: Zanamivir versus placebo for prophylaxis. Symptomatic influenza in prophylaxis of individuals.




Figure 7: Zanamivir versus placebo for prophylaxis. Symptomatic influenza in post-exposure prophylaxis of households.




Figure 8: Zanamivir versus placebo for prophylaxis. Asymptomatic influenza in post-exposure prophylaxis of individuals.




Figure 9: Zanamivir versus placebo for prophylaxis. Asymptomatic influenza in post-exposure prophylaxis of households.




Figure 10: Zanamivir versus placebo for treatment. Complications: pneumonia confirmed with X-ray in adult treatment.




Figure 11: Complications: Mixed verified and unverified pneumonia in adult treatment.




Figure 12: Complications: self reported investigator mediated unverified pneumonia in adult prophylaxis.




Figure 13: Complications: bronchitis in adult treatment.




Figure 14: Complications: otitis media in adult treatment.




Figure 15: Complications: sinusitis in adult treatment.




Figure 16: Complications classified as serious or leading to study withdrawal in adult treatment.




Figure 17: Complications classified as serious or leading to study withdrawal in adult prophylaxis.




Figure 18: Adverse events: nausea and vomiting in adult treatment (on-treatment)

